期刊文献+

How Mutations Affecting the Ligand-receptor Interactions: a Combined MD and QM/MM Calculation on CYP2E1 and Its Two Mutants 被引量:2

How Mutations Affecting the Ligand-receptor Interactions: a Combined MD and QM/MM Calculation on CYP2E1 and Its Two Mutants
原文传递
导出
摘要 Cytochrome P450(CYP) 2El is a dual function monoxygenase with a crucial role in the metabolism of 6% of drugs on the market at present. The enzyme is of tremendous interest for its association with alcohol consumption, diabetes, obesity and fasting. Despite the abundant experimental mutagenesis data, the molecular origin and the structural motifs for the enzymatic activity deficiencies have not been rationalized at the atomic level. In this regard, we have investigated the effects of mutation on the structural and energetic characteristics upon single point mutations in CYP2E1, N219D and $366C. The molecular dynamics(MD) simulation combined with quantum mechanics/molecular mechanics(QM/MM) and noncovalent interaction(NCI) analysis was carried out on CYP2EI and its two mutants. The results highlight the critical role of Phe207, which is responsible for both structural flexibility and energetic variation, shortening the gap between the theory and the experimentally observed results of enzymatic activity decrease, The underlying molecular mechanism of the enzymatic activity deficiencies for mutants may be attributed to the changes of spatial position of Phe207 in the two mutants. This work provides particular explanations to how mutations affect ligand-receptor interactions based on combined MD and QM/MM calculations. Furthermore, the mutational effects on the activity of CYP2E1 obtained in the present study are beneficial to both the experimental and the computational works of CYPs and may allow researchers to achieve desirable changes in enzymatic activity. Cytochrome P450(CYP) 2El is a dual function monoxygenase with a crucial role in the metabolism of 6% of drugs on the market at present. The enzyme is of tremendous interest for its association with alcohol consumption, diabetes, obesity and fasting. Despite the abundant experimental mutagenesis data, the molecular origin and the structural motifs for the enzymatic activity deficiencies have not been rationalized at the atomic level. In this regard, we have investigated the effects of mutation on the structural and energetic characteristics upon single point mutations in CYP2E1, N219D and $366C. The molecular dynamics(MD) simulation combined with quantum mechanics/molecular mechanics(QM/MM) and noncovalent interaction(NCI) analysis was carried out on CYP2EI and its two mutants. The results highlight the critical role of Phe207, which is responsible for both structural flexibility and energetic variation, shortening the gap between the theory and the experimentally observed results of enzymatic activity decrease, The underlying molecular mechanism of the enzymatic activity deficiencies for mutants may be attributed to the changes of spatial position of Phe207 in the two mutants. This work provides particular explanations to how mutations affect ligand-receptor interactions based on combined MD and QM/MM calculations. Furthermore, the mutational effects on the activity of CYP2E1 obtained in the present study are beneficial to both the experimental and the computational works of CYPs and may allow researchers to achieve desirable changes in enzymatic activity.
出处 《Chemical Research in Chinese Universities》 SCIE CAS CSCD 2015年第6期1029-1038,共10页 高等学校化学研究(英文版)
基金 Supported by the National Natural Science Foundation of China(No.21273095).
关键词 Cytochrome P450(CYP) 2El Molecular dynamics(MD) simulation Quantum mechanics/molecular mechanics(QM/MM ONIOM) calculation Noncovalent interaction(NCI) analysis Cytochrome P450(CYP) 2El Molecular dynamics(MD) simulation Quantum mechanics/molecular mechanics(QM/MM, ONIOM) calculation Noncovalent interaction(NCI) analysis
  • 相关文献

参考文献76

  • 1Danielson E, Current Drug Metabolism, 2002, 3, 561.
  • 2Nelson D. R., Archives of Biochemistry and Biophysics, 1999, 369, 1.
  • 3Watanabe K. P., Kawai Y. K., Ikenaka Y., Kawata M., Ikushiro S. I., Sakaki T., Ishizuka M., PloS One, 2013, 8, e75689.
  • 4Scott E. E., Halpert J. R., Trends in Biochemical Sciences, 2005, 30, 5.
  • 5Park H., Lee S., SuhJ.,J. Am. Chem. Soc., 2005, 127, 13634.
  • 6Walsh A. A., Szklarz G. D., Scott E. E., Journal of Biological Che- mistry, 2013, 288, 12932.
  • 7Miller G. P., Expert Opin. Drug Met., 2008, 4, 1053.
  • 8Trafalis D. T., Panteli E. S., Grivas A., Tsigris C., Karamanakos P. N., Expert Opinion on Drug Metabolism & Toxicology, 2010, 6, 307.
  • 9Ioannides C., Lewis V., David F., Current Topics in Medicinal Che- mistry, 2004, 4, 1767.
  • 10Nanji A. A., Zhan S., Sadrzadeh S., Dannenberg A. J., Tahan S. R., Waxman D. J., Alcoholism: Clinical and Experimental Research, 1994, 18, 1280.

同被引文献8

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部